Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication

Microbes and Infection

Volumn 10, Issue 5, 2008, Pages 471-480

  Amet, Tohti ^a   Nonaka, Mizuho ^a   Dewan, Md Zahidunnabi ^a,b   Saitoh, Yasunori ^a   Qi, Xiaohua ^a,b   Ichinose, Shizuko ^c   Yamamoto, Naoki ^a,b   Yamaoka, Shoji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

HIV 1; Prenylation; Rab11a; Small GTPases; Statins

Indexed keywords

CHOLESTEROL; FARNESYL TRANS TRANSFERASE; MEVINOLIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAB11 PROTEIN; RAB11A GTPASE PROTEIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL CULTURE; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPOPHILICITY; NONHUMAN; NONOBESE DIABETIC MOUSE; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; VIRION; VIRUS INFECTION; VIRUS REPLICATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE, TUMOR; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, ELECTRON, TRANSMISSION; POLYISOPRENYL PHOSPHATES; PROTEIN PRECURSORS; PROTEIN PRENYLATION; RAB GTP-BINDING PROTEINS; RNA INTERFERENCE; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 43649093166     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.01.009     Document Type: Article

References (30)

1. Han Y., Wind-Rotolo M., Yang H.C., Siliciano J.D., and Siliciano R.F. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5 (2007) 95-106
2. Blankson J.N., Persaud D., and Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53 (2002) 557-593
3. Chun T.W., Davey Jr. R.T., Ostrowski M., Shawn Justemente J., Engel D., Mullins J.I., and Fauci A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6 (2000) 757-761
4. del Real G., Jimenez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gomez-Mouton C., Alegret M., Pena J.M., Rodriguez-Zapata M., Alvarez-Mon M., Martinez-A C., and Manes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200 (2004) 541-547
5. Gilbert C., Bergeron M., Methot S., Giguere J.F., and Tremblay M.J. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol. 18 (2005) 474-489
6. Giguere J.F., and Tremblay M.J. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J. Virol. 78 (2004) 12062-12065
7. Audoly G., Popoff M.R., and Gluschankof P. Involvement of a small GTP binding protein in HIV-1 release. Retrovirology 2 (2005) 48
8. Nabatov A.A., Pollakis G., Linnemann T., Paxton W.A., and de Baar M.P. Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS ONE 2 (2007) e470
9. Bocan T.M. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs 3 (2002) 1312-1317
10. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6 (2007) 541-555
11. Gelb M.H., Brunsveld L., Hrycyna C.A., Michaelis S., Tamanoi F., Van Voorhis W.C., and Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nat. Chem. Biol. 2 (2006) 518-528
12. McTaggart S.J. Isoprenylated proteins. Cell. Mol. Life Sci. 63 (2006) 255-267
13. Grosshans B.L., Ortiz D., and Novick P. Rabs and their effectors: achieving specificity in membrane traffic. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 11821-11827
14. Pfeffer S., and Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat. Rev. Mol. Cell Biol. 5 (2004) 886-896
15. Joberty G., Tavitian A., and Zahraoui A. Isoprenylation of Rab proteins possessing a C-terminal CaaX motif. FEBS Lett. 330 (1993) 323-328
16. Murray J.L., Mavrakis M., McDonald N.J., Yilla M., Sheng J., Bellini W.J., Zhao L., Le Doux J.M., Shaw M.W., Luo C.C., Lippincott-Schwartz J., Sanchez A., Rubin D.H., and Hodge T.W. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J. Virol. 79 (2005) 11742-11751
17. Ullrich O., Reinsch S., Urbe S., Zerial M., and Parton R.G. Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol. 135 (1996) 913-924
18. Varthakavi V., Smith R.M., Martin K.L., Derdowski A., Lapierre L.A., Goldenring J.R., and Spearman P. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7 (2006) 298-307
19. Hamamoto Y., Takamatsu K., Kobayashi S., Yamaguchi K., Yamamoto N., and Kobayashi N. Characterization of human T-cell lines harboring defective human immunodeficiency virus type 1. Virus genes 3 2 (1989) 141-152
20. Dewan M.Z., Terashima K., Taruishi M., Hasegawa H., Ito M., Tanaka Y., Mori N., Sata T., Koyanagi Y., Maeda M., Kubuki Y., Okayama A., Fujii M., and Yamamoto N. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J. Virol. 77 (2003) 5286-5294
21. Fernie B.F., Poli G., and Fauci A.S. Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J. Virol. 65 (1991) 3968-3971
22. Folks T.M., Justement J., Kinter A., Dinarello C.A., and Fauci A.S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238 (1987) 800-802
23. Perlmen M., and Resh M.D. Identification of an intracellular trafficking and assembly pathway for HIV-1 gag. Traffic 7 (2006) 731-745
24. Grigorov B., Arcanger F., Roingeard P., Darlix J.L., and Muriaux D. Assembly of infectious HIV-1 in human epithelial and T-lymphoblastic cell lines. J. Mol. Biol. 359 (2006) 848-862
25. Ono A., and Freed E.O. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J. Virol. 78 (2004) 1552-1563
26. Pelchen-Matthews A., Kramer B., and Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J. Cell Biol. 162 (2003) 443-455
27. Raposo G., Moore M., Innes D., Leijendekker R., Leigh-Brown A., Benaroch P., and Geuze H. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 3 (2002) 718-729
28. Resh M.D. Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. AIDS Rev. 7 (2005) 84-91
29. Savina A., Vidal M., and Colombo M.I. The exosome pathway in K562 cells is regulated by Rab11. J. Cell Sci. 115 (2002) 2505-2515
30. Vogt A., Sun J., Qian Y., Hamilton A.D., and Saïd M. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 in a p53-independent manner. J. Biol. Chem. 272 (1997) 27224-27229